On The Wings Of Lantus: Sanofi Sees Clearer Skies Ahead In Diabetes
Executive Summary
With the removal of a near-term competitive threat to Sanofi’s hallmark insulin franchise, 2013 is poised to be a momentum-building year for the big pharma, and more specifically, its diabetes business. The opportunity can’t come too soon, as the company launches the GLP-1 agonist Lyxumia into a crowded and fiercely competitive field.
You may also be interested in...
On The Offense: Sanofi Suits Up For A Game Change
Having exited its patent cliff and advanced several drugs into late-stage development, Sanofi is moving into a new commercial-centric phase. Its future looks bright, but success is not guaranteed.
Lilly Preps To File A Rival To Lantus, But Safety Remains In Question
Eli Lilly’s novel basal insulin peglispro demonstrated superiority to Sanofi’s Lantus in three Phase III trials on blood sugar control, but the insulin also increased triglycerides and liver enzymes in patients.
Lilly Preps To File A Rival To Lantus, But Safety Remains In Question
Eli Lilly’s novel basal insulin peglispro demonstrated superiority to Sanofi’s Lantus in three Phase III trials on blood sugar control, but the insulin also increased triglycerides and liver enzymes in patients.